HMGB1、PCT、TGF-β1水平与新生儿重症肺炎病情相关性及对预后的影响

doi:10.3760/cma.j.issn.1007-1245.2024.22.004

摘要/Abstract

摘要：

目的　探讨高迁移率族蛋白B1（high mobility group box 1，HMGB1）、降钙素原（procalcitonin，PCT）、转化生长因子β1（transforming growth factor β1，TGF-β1）水平与新生儿重症肺炎病情相关性及对预后的影响。方法　选取2020年9月至2023年12月在咸阳市中心医院新生儿科诊治的重症肺炎新生儿90例为研究对象，根据随访30 d内的情况分为预后良好组（64例）与预后不良组（26例）。比较两组入院当天（D0）、入院1 d（D1）、入院3 d（D3）、入院5 d（D5）、入院7 d（D7）血清HMGB1、PCT、TGF-β1水平及小儿危重病例评分（Pediatric Critical Illness Score，PCIS）、急性生理与慢性健康评估Ⅱ（Acute Physiology and Chronic Health Evaluation Ⅱ，APACHEⅡ）评分，并计算D7/D1的比值（以ratio表示），分析各血清指标水平变化与病情的相关性和对预后的影响。采用独立样本t检验、χ²检验、Pearson相关性分析。结果　预后不良组男13例，女13例，胎龄（37.58±1.13）周，日龄（11.43±1.47）d；预后良好组男33例，女31例，胎龄（38.64±1.06）周，日龄（10.95±1.59）d。预后不良组D0～D7血清HMGB1、PCT、TGF-β1水平及APACHEⅡ评分高于预后良好组，PCIS低于预后良好组（均P<0.05）。血清HMGB1-ratio、PCT-ratio、TGF-β1-ratio与PCIS-ratio呈负相关，与APACHEⅡ-ratio呈正相关（均P<0.05）。logistic回归分析显示，HMGB1-ratio、PCT-ratio、TGF-β1-ratio、PCIS-ratio、APACHEⅡ-ratio均为重症肺炎新生儿预后不良的影响因素（均P<0.05）。血清HMGB1-ratio、PCT-ratio、TGF-β1-ratio预测重症肺炎新生儿预后不良的曲线下面积分别为0.823、0.820、0.923，三者联合预测的曲线下面积为0.977。结论　新生儿重症肺炎中HMGB1、PCT、TGF-β1水平与病情严重度和预后密切相关。预后不良患儿这些指标水平较高，这些指标的比值可有效预测疾病预后，三者联合预测准确度更高，有助于评估病情和预后。

关键词:

高迁移率族蛋白B1, 降钙素原, 转化生长因子β1, 新生儿, 重症肺炎

Abstract:

Objective　To explore the correlations between high mobility group box 1 (HMGB1), procalcitonin (PCT), and transforming growth factor β1 (TGF-β1) levels with the severity and prognosis of neonatal severe pneumonia. Methods　A total of 90 neonates with severe pneumonia diagnosed and treated in the Department of Neonatology, Xianyang Central Hospital from September 2020 to December 2023 were selected as the study subjects, and were divided into a good prognosis group (64 cases) and a poor prognosis group (26 cases) according to the condition within 30 days of follow-up. Serum HMGB1, PCT, and TGF-β1 levels, Pediatric Critical Illness Score (PCIS), and Acute Physiology and Chronic Health Evaluation Ⅱ (APACHEⅡ) score were compared between the two groups on the day of admission (D0) and 1 day after admission (D1), 3 days after admission (D3), 5 days after admission (D5), and 7 days after admission (D7), and the ratio of D7/D1 was calculated (represented as the ratio value). The correlations between the changes of serum indexes and the condition and the influence on prognosis were analyzed. Independent sample t test, χ² test, and Pearson correlation analysis were used. Results　In the poor prognosis group, there were 13 boys and 13 girls, with a gestational age of (37.58±1.13) weeks, aged (11.43±1.47) days. In the good prognosis group, there were 33 boys and 31 girls, with a gestational age of (38.64±1.06) weeks, aged (10.95±1.59) days. The levels of serum HMGB1, PCT, and TGF-β1 and APACHEⅡ score in the poor prognosis group were higher than those in the good prognosis group from D0 to D7, and the PCIS was lower than that in the good prognosis group (all P<0.05). The ratio values of serum HMGB1, PCT, and TGF-β1 were negatively correlated with the PCIS ratio value, and positively correlated with the APACHEⅡ ratio value (all P<0.05). Logistic regression analysis showed that HMGB1-ratio, PCT-ratio, TGF-β1-ratio, PCIS-ratio, and APACHEⅡ-ratio were all influencing factors for poor prognosis in neonates with severe pneumonia (all P<0.05). The areas under the curves of serum HMGB1-ratio, PCT-ratio, and TGF-β1-ratio in predicting poor prognosis in neonates with severe pneumonia were 0.823, 0.820, and 0.923, respectively, and the area under the curve of the combined prediction of the three was 0.977. Conclusions　The levels of HMGB1, PCT, and TGF-β1 in neonatal severe pneumonia are closely related to the severity of the disease and prognosis. The levels of these indicators are higher in the children with poor prognosis, and the ratio values of these indicators can effectively predict the prognosis. The combined prediction of the three indicators has a higher accuracy, which helps to evaluate the condition and prognosis.

Key words:

High mobility group box 1, Procalcitonin, Transforming growth factor β1, Neonates, Severe pneumonia

鲁旭赵英娟李丹青.

HMGB1、PCT、TGF-β1水平与新生儿重症肺炎病情相关性及对预后的影响 [J]. 国际医药卫生导报, 2024, 30(22): 3712-3717.

Lu Xu, Zhao Yingjuan, Li Danqing.

Correlations of HMGB1, PCT, and TGF-β1 levels with the severity and prognosis of neonatal severe pneumonia [J]. International Medicine and Health Guidance News, 2024, 30(22): 3712-3717.

参考文献

[1] 田静,惠晓君,张靖,等.PPARγ基因多态性与新生儿肺炎易感性及血清炎症细胞因子的关系[J].中国现代医学杂志,2021,31(3):31-35. DOI:10.3969/j.issn.1005-8982.2021. 03.006.
[2] 杨丽,陈燕华,徐凤玲.吸入一氧化氮联合高频震荡通气治疗新生儿重症肺炎的临床效果分析[J].河北医科大学学报,2018,39(9):1038-1042. DOI:10.3969/j.issn.1007-3205. 2018.09.011.
[3] 李星,李竹英,王珏.平喘颗粒对哮喘气道相关炎症因子及肺组织HMGB1、TLR4表达的影响[J].中国中医急症,2021,30(6):941-944,949. DOI:10.3969/j.issn.1004- 745X.2021.06.001.
[4] 王强,黄欢欢,罗勇.不同预后老年COPD患者血清PCT及炎症因子水平检测的临床意义[J].中国急救复苏与灾害医学杂志,2023,18(4):518-521. DOI:10.3969/j.issn.1673- 6966.2023.04.023.
[5] 陈珊,朱俊德,赵雪,等.神经干细胞来源外泌体对脑缺血再灌注损伤大鼠星形胶质细胞TGF-β1信号转导与炎症因子的影响[J].实用医学杂志,2023,39(13):1600-1605,1613. DOI:10.3969/j.issn.1006-5725.2023.13.002.
[6] Wang S, Zhang Y. HMGB1 in inflammation and cancer[J]. J Hematol Oncol, 2020, 13(1):116. DOI: 10.1186/s13045- 020-00950-x.
[7] Creamer AW, Kent AE, Albur M. Procalcitonin in respiratory disease: use as a biomarker for diagnosis and guiding antibiotic therapy[J]. Breathe (Sheff), 2019, 15(4):296-304. DOI: 10.1183/20734735.0258-2019.
[8] Hao Y, Baker D, Ten Dijke P. TGF-β-mediated epithelial-mesenchymal transition and cancer metastasis[J]. Int J Mol Sci, 2019, 20(11):2767. DOI: 10.3390/ijms20112767.
[9] Lodyga M, Hinz B. TGF-β1 - a truly transforming growth factor in fibrosis and immunity[J]. Semin Cell Dev Biol, 2020, 101:123-139. DOI: 10.1016/j.semcdb.2019.12.010.
[10] Lin L, Li J, Song Q, et al. The role of HMGB1/RAGE/TLR4 signaling pathways in cigarette smoke-induced inflammation in chronic obstructive pulmonary disease[J]. Immun Inflamm Dis, 2022, 10(11):e711. DOI: 10.1002/iid3.711.
[11] 瞿明奎,杜斌,姜赛赛,等.泻白散加减治疗对肺癌急性放射性肺炎(肺热炽盛证)患者血清TGF-β1、PCT水平的影响[J].四川中医,2024,42(1):100-103.
[12] 沈晓明,王卫平.儿科学[M].7版.北京:人民卫生出版社,2011:158-161.
[13] 肖飞,张鹏,王润智.血清SAA、HMGB1对小儿重症肺炎预后的预测价值研究[J].临床肺科杂志,2021,26(7):1008-1012. DOI:10.3969/j.issn.1009-6663.2021.07.009.
[14] 赵丽,孙俏丽.超声对患儿肺部感染的诊断价值及与血清PCT、PCIS评分的相关性[J].影像科学与光化学,2022,40(3):555-559. DOI:10.7517/issn.1674-0475.211123.
[15] 张强,ZHAO Liang,许永华,等.急性生理学与慢性健康状况评分系统Ⅱ评分及凝血指标对老年脓毒症患者预后的评估作用[J].中国危重病急救医学,2008,20(8):493-494. DOI:10.3321/j.issn:1003-0603.2008.08.013.
[16] de Benedictis FM, Kerem E, Chang AB, et al. Complicated pneumonia in children[J]. Lancet, 2020, 396(10253):786-798. DOI: 10.1016/S0140-6736(20)31550-6.
[17] Horiachko AN, Sukalo AV. Prognostic model for determining the probability of congenital pneumonia in full-term newborns[J]. CHILD`S HEALTH, 2019, 14(4): 256-261. DOI:10.22141/2224-0551.14.4.2019.174040.
[18] Dell'Orto V, Raschetti R, Centorrino R, et al. Short- and long-term respiratory outcomes in neonates with ventilator-associated pneumonia[J]. Pediatr Pulmonol, 2019, 54(12):1982-1988. DOI: 10.1002/ppul.24487.
[19] Yang H, Wang H, Andersson U. Targeting inflammation driven by HMGB1[J]. Front Immunol, 2020, 11:484. DOI: 10.3389/fimmu.2020.00484.
[20] Paudel YN, Angelopoulou E, Piperi C, et al. Enlightening the role of high mobility group box 1 (HMGB1) in inflammation: updates on receptor signalling[J]. Eur J Pharmacol, 2019, 858:172487. DOI: 10.1016/j.ejphar.2019.172487.
[21] Foglio E, Pellegrini L, Russo MA, et al. HMGB1-mediated activation of the inflammatory-reparative response following myocardial infarction[J]. Cells, 2022, 11(2):216. DOI: 10.3390/cells11020216.
[22] Lu H, Zhang Z, Barnie PA, et al. Dual faced HMGB1 plays multiple roles in cardiomyocyte senescence and cardiac inflammatory injury[J]. Cytokine Growth Factor Rev, 2019, 47:74-82. DOI: 10.1016/j.cytogfr.2019.05.009.
[23] Batlle E, Massagué J. Transforming growth factor-β signaling in immunity and cancer[J]. Immunity, 2019, 50(4):924-940. DOI: 10.1016/j.immuni.2019.03.024.
[24] Kodera Y, Kohno T, Konno T, et al. HMGB1 enhances epithelial permeability via p63/TGF-β signaling in lung and terminal bronchial epithelial cells[J]. Tissue Barriers, 2020, 8(4):1805997. DOI: 10.1080/21688370.2020. 1805997.
[25] Zou H, Ming B, Li J, et al. Extracellular HMGB1 contributes to the chronic cardiac allograft vasculopathy/fibrosis by modulating TGF-β1 signaling[J]. Front Immunol, 2021, 12:641973. DOI: 10.3389/fimmu.2021.641973.
[26] 代春英,程丽,朱天吉,等.肺炎支原体感染临床特征及TGF-β1/Smads通路变化[J].中华医院感染学杂志,2023,33(22):3423-3427. DOI:10.11816/cn.ni.2023-230406.
[27] 翁珍丽,杨勤,方雪彬.基于NLRP3/IL-1β/TGF-β1通路探讨萝卜硫素对脂多糖诱导的小鼠肺炎的改善作用[J].中国老年学杂志,2023,43(22):5579-5583. DOI:10.3969/j.issn.1005-9202.2023.22.055.
[28] Wu SC, Liang CX, Zhang YL, et al. Elevated serum procalcitonin level in patients with chronic kidney disease without infection: a case-control study[J]. J Clin Lab Anal, 2020, 34(2):e23065. DOI: 10.1002/jcla.23065.
[29] Baranowsky A, Appelt J, Kleber C, et al. Procalcitonin exerts a mediator role in septic shock through the calcitonin gene-related peptide receptor[J]. Crit Care Med, 2021, 49(1):e41-e52. DOI: 10.1097/CCM.0000000000004731.
[30] Liu F, Li L, Xu M, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19[J]. J Clin Virol, 2020, 127:104370. DOI: 10.1016/j.jcv.2020.104370.
[31] Sun Q, Gao Y, Qiao L, et al. 25(OH)-Vitamin D alleviates neonatal infectious pneumonia via regulating TGFβ-mediated nuclear translocation mechanism of YAP/TAZ[J]. Bioengineered, 2021, 12(1):8931-8942. DOI: 10.1080/21655979.2021.1990000.
[32] Tang Z, Jiang M, Ou-Yang Z, et al. High mobility group box 1 protein (HMGB1) as biomarker in hypoxia-induced persistent pulmonary hypertension of the newborn: a clinical and in vivo pilot study[J]. Int J Med Sci, 2019, 16(8):1123-1131. DOI: 10.7150/ijms.34344.